A new study found a correlation between an increase in emergency cardiovascular events among people under 40 years of age during the launch of Israel’s COVID-19 vaccine program.
Published in the Nature journal, researchers utilized data from the Israel National Emergency Medical Services between 2019 and 2021 that evaluated emergency, or EMS, calls among 16- to 39-year-olds across Israel “with potential factors including COVID-19 infection and vaccination rates.”
They found that there was a 25 percent increase in EMS calls between January 2021 to May 2021, as compared with the years 2019 and 2020. Israel, which primarily uses Pfizer’s mRNA vaccine, launched its COVID-19 vaccine program in late December 2020.
“The weekly emergency call counts were significantly associated with the rates of 1st and 2nd vaccine doses administered to this age group but were not with COVID-19 infection rates,” they found. “While not establishing causal relationships, the findings raise concerns regarding vaccine-induced undetected severe cardiovascular side-effects and underscore the already established causal relationship between vaccines and myocarditis, a frequent cause of unexpected cardiac arrest in young individuals.”
They recommend that when evaluating possible vaccine side-effects and COVID-19 outcomes, officials should incorporate EMS data and relevant data to identify potential new health trends such as an increase in EMS calls, and “promptly investigate potential underlying causes.”
A recent study carried out by Swedish researchers across populations in Finland, Denmark, Sweden, and Norway suggested that heart inflammation requiring hospital care was more common among people who received COVID-19 vaccines than individuals who did not.
“These extra cases among men aged 16 to 24 correspond to a 5 times increased risk after Comirnaty and 15 times increased risk after Spikevax compared to unvaccinated,” Dr. Rickard Ljung, a professor and physician at the Swedish Medical Products Agency who was involved in the study, told The Epoch Times last week. Spikevax is the name for Moderna’s COVID-19 vaccine, while Comirnaty is Pfizer’s vaccine.
His team found that myocarditis or pericarditis rates are higher than the levels in an unvaccinated cohort, or 38 per 100,000 after second doses of the mRNA vaccines were administered.
